[{"from": "human", "value": "Provide a brief overview of this molecule. [C][C@H1][Branch1][N][/C][=C][/C@H1][Branch1][C][C][C][Branch1][C][C][C][C@H1][C][C][C@@H1][C@@][Ring1][Branch1][Branch2][Ring1][Branch1][C][C][C][/C][\\-Ring1][=Branch1][=C][\\C][=C][\\C][C@H1][Branch1][#Branch1][C][C][C][/-Ring1][=Branch1][=C][O][C]"}, {"from": "gpt", "value": "The molecule is an inactivated vitamin D analog. It is synthesized by some plants in the presence of UVB light. The production of ergocalciferol was prompted by the identification of dietary deficiency, more specifically vitamin D, as the main causative factor for the development of rickets. Ergocalciferol was isolated for the first time from yeast in 1931 and its structure was elucidated in 1932.  Ergocalciferol is considered the first vitamin D analog and is differentiated from [cholecalciferol] by the presence of a double bond between C22 and C23 and the presence of a methyl group at C24. These modifications reduce the affinity of ergocalciferol for the vitamin D binding protein resulting in faster clearance, limits its activation, and alters its catabolism.  The first approved product containing ergocalciferol under the FDA records was developed by US Pharm Holdings and was FDA approved in 1941."}]